Effects of cocaine prior to and during bupropion maintenance in cocaine-abusing volunteers

Drug and Alcohol Dependence

Volumn 63, Issue 2, 2001, Pages 155-167

  Oliveto, Alison ^a,b   McCance Katz, F Elinore ^a,b   Singha, Amrita ^a,b   Petrakis, Ismene ^a,b   Hameedi, Faiq ^a   Kosten, Thomas R ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

Author keywords

Bupropion; Cocaine; Pharmacotherapy

Indexed keywords

AMFEBUTAMONE; COCAINE;

ADULT; ARTICLE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RESPONSE; CLINICAL ARTICLE; CLINICAL TRIAL; COCAINE DEPENDENCE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; FEMALE; HUMAN; HUMAN EXPERIMENT; MAINTENANCE THERAPY; MALE; PERFORMANCE; PRIORITY JOURNAL; RATING SCALE; SELF REPORT; TREATMENT OUTCOME;

ADMINISTRATION, INTRANASAL; ADULT; AFFECT; AROUSAL; BUPROPION; COCAINE; COCAINE-RELATED DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; PREMEDICATION; SINGLE-BLIND METHOD;

EID: 0035400641     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0376-8716(00)00198-8     Document Type: Article

References (67)

1. Ambre J.J., Belknap S.M., Nelson J., Ruo T.I., Shin S.G., Atkinson A.J. Acute tolerance to cocaine in humans. Clin. Pharmacol. Ther. 44:1988;1-8.
2. Andersen P.H. Biochemical and pharmacological characterization of [3H]GBR12935 binding in vitro to rat striatal membranes: Labeling of the dopamine uptake complex. J. Neurochem. 48:1987;1887-1896.
3. Beitner-Johnson D., Nestler E.J. Basic neurobiology of cocaine: Actions within the mesolimbic dopamine system. Kosten T.R., Kleber H.B. Clinician's Guide to Cocaine Abuse'. 1992;Guilford Press, New York.
4. Bergman J., Madras B.K., Johnson S.E., Spealman R.D. Effects of cocaine and related drugs in nonhuman primates. III. Self-administration by squirrel monkeys. J. Pharmacol. Exper. Ther. 251:1989;150-155.
5. Best S.E., Malison R.T., Wallace E.A., Zoghbi S.S., Zea-Ponce Y., Baldwin R.M., Innis R.B., Kosten T.R. SPECT imaging of the dopamine transporter in cocaine abstinence: Preliminary studies using [123-I]b-CIT. Harris L.S. Problems of Drug Dependence. 1994;1994 Supt. of Docs., US Government Printing Office, Washington, DC. National Institute on Drug Abuse Research Monograph No. 153.
6. Blitzer R.D., Becker R.E. Characterization of the bupropion cue in the rat: Lack of evidence for a dopaminergic mechanism. Psychopharmacology. 85:1985;173-177.
7. Collins E.D., Ward A.S., McDowell D.M., Foltin R.W., Fischman M.W. The effects of memantine on the subjective, reinforcing and cardiovascular effects of cocaine in humans. Behav. Pharmacol. 9:1998;587-598.
8. Davidson J. Seizures and bupropion: A review. J. Clin. Psychiatry. 50:1989;256-261.
9. Farid F.F., Wenger T.L., Tsai S.Y., Singh B.N., Stern W.C. Use of bupropion in patients who exhibit orthostatic hypotension on tricyclic antidepressants. J. Clin. Psychiatry. 44:1983;170-173.
10. Ferris R.M., Beaman O.J. Bupropion: A new antidepressant drug, the mechanism of action of which is not associated with down-regulation of post-synaptic beta-adrenergic, serotoninergic (5HT2) alpha2-adrenergic, imipramine and dopaminergic receptors in the brain. Neuropharmacology. 22:1983;1257-1267.
11. Fischman M.W., Schuster C.R., Resnekov L., Shick F.E., Krasnegor N.A., Fennell W., Freedman D.X. Cardiovascular and subjective effects of intravenous cocaine administration in humans. Arch. Gen. Psychiatry. 33:1976;983-989.
12. Fischman M.W., Foltin R.W., Nestadt G., Pearlson G.D. Effects of desipramine maintenance on cocaine self-administration by humans. J. Pharmacol. Exp. Ther. 253:1990;760-770.
13. Foltin R.W., Fischman M.W. Assessment of abuse liability of stimulant drugs in humans: A methodological survey. Drug Alcohol Depend. 28:1991;3-48.
14. Foltin R.W., Fischman M.W., Pedroso J.J., Pearlson G.D. Repeated intranasal cocaine administration: lack of tolerance to pressor effects. Drug Alcohol Depend. 22:1988;169-177.
15. Gawin F.H., Kleber H.D. Abstinence symptomatology and psychiatric diagnosis in cocaine abusers: Clinical observations. Arch. Gen. Psychiatry. 43:1986;107-113.
16. Griffith J.D., Carranza J., Griffith C., Miller L.E. Bupropion: clinical assay for amphetamine-like abuse potential. J. Clin. Psychiatry. 44:1983;206-208.
17. Haney M., Foltin R.W., Fischman M.W. Effects of pergolide on intravenous cocaine self-administration in men and women. Psychopharmacology. 137:1998;15-24.
18. Haney M., Collins E.D., Wars A.S., Foltin R.W., Fischman M.W. Effects of a selective dopamine D1 agonist (ABT-431) on smoked cocaine self-administration in humans. Psychopharmacology. 143:1999;102-110.
19. Hatsukami D., Keenan R., Halikas J., Pentel P.R., Hartman Brauer L. Effects of carbamazepine in acute responses to smoked cocaine-base in human cocaine users. Psychopharmacology. 104:1991;120-124.
20. Higgins S.T., Bickel W.K., Hughes J.R., Lynn M., Capeless M.A., Fenwick J.W. Effects of intranasal cocaine on human learning, performance and physiology. Psychopharmacology. 102:1990;451-458.
21. Jasinski D.R. Assessment of the abuse potential of morphine-like drugs (methods used in man). Martin W.R. Drug Addiction I. 1977;197-258 Springer-Verlag, New York.
22. Jatlow P., Elsworth J.D., Bradberry C.W., Winder G., Taylor J.R., Russell R., Roth R.H. Cocaethylene: a neuropharmacologically active metabolite associated with concurrent cocaine-ethanol ingestion. Life Sci. 48:1991;1787-1794.
23. Jimerson D.C. Role of dopamine mechanisms in the affective disorders. Meltzer H.Y. Psychopharmacology: The Third Generation of Progress. 1987;505-511 Raven Press, New York.
24. Johanson C.E., Barrett J.E. The discriminative stimulus effects of cocaine in pigeons. J. Pharmacol. Exper. Ther. 267:1993;1-8.
25. Jones C.N., Howard J.L., McBennett S.T. Stimulus properties of antidepressants in the rat. Psychopharmacology. 67:1980;111-118.
26. Kleven M.S., Anthony E.W., Woolverton W.L. Pharmacological characterization of the discriminative stimulus effects of cocaine in rhesus monkeys. J. Pharmacol. Exp. Ther. 317:1990;254-312.
27. Koob G.F. Separate neurochemical substrates for cocaine and heroin reinforcement. Church R.M., Commons M.L., Stellar J., Wagner A.R. Quantitative Analyses of Behavior: Biological Determinants of Behavior. 7:1987;139-156 Lawrence Erlbaum, Hillsdale, NJ.
28. Kosten T.R. Neurobiology of abused drugs: Opioids and stimulants. J. Nerv. Ment. Dis. 178:1990;217-227.
29. Kosten T.R., Gawin F.H., Silverman D.G., Fleming J., Compton M., Jatlow P., Byck R. Intravenous cocaine challenges during desipramine maintenance. Neuropsychopharmacology. 7:1992a;169-176.
30. Kosten T.R., Silverman D.G., Fleming J., Kosten T.A., Gawin F.H., Compton M., Jatlow P., Byck R. Intravenous cocaine challenges during naltrexone maintenance: A preliminary study. Biol. Psychiatry. 32:1992b;543-548.
31. Kranzler H.R., Wallington D.J. Serum prolactin level, craving, and early discharge from treatment in cocaine-dependent patients. Am. J. Drug Alcohol Abuse. 18:(2):1992;187-195.
32. Lamb R.J., Griffiths R.R. Self-administration in baboons and the discriminative stimulus effects in rats of bupropion, nomifensine, diclofensine and imipramine. Psychopharmacology. 102:1990;183-190.
33. 123I]b-CIT SPECT measures of dopamine transporter availability in human cocaine addicts. Psychopharmacology. 122:1995;358-362.
34. Margolin A., Kosten T.R., Avants K., Wilkins J., Ling W., Beckson M., Arndt I.O., Cornish J., Ascher J.A., Li S.H., Bridge P. A multicenter trial of bupropion for cocaine dependence in methadone-maintained patients. Drug Alcohol Depend. 40:1995;125-131.
35. Martin W.R., Sloan J.W., Sapira J.D., Jasinski D.R. Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine and methylphenidate in man. Clin. Pharmacol. Ther. 12:1971;245-258.
36. McCance-Katz E.F., Kosten T.R., Jatlow P. Chronic disulfiram treatment effects on intranasal cocaine administration: initial results. Biol. Psychiatry. 43:1998a;540-543.
37. McCance-Katz E.F., Kosten T.R., Jatlow P. Concurrent use of cocaine and alcohol is more potent and potentially more toxic than use of either alone - a multiple dose study. Biol. Psychiatry. 44:1998b;250-259.
38. McLeod D.R., Griffiths R.R., Bigelow G.E., Yingling J. An automated version of the digit symbol substitution test (DSST). Behav. Res. Meth. Instrum. 14:1982;463-466.
39. Melia K.F., Spealman R.D. Pharmacological characterization of the discriminative-stimulus effects of GBR 12909. J. Pharmacol. Exper. Ther. 258:1991;626-632.
40. Mendelson J.H., Teoh S., Lange U., Mello N.K., Weiss R., Skupny A., Ellingboe J. Anterior pituitary, adrenal, and gonadal hormones during cocaine withdrawal. Am. J. Psychiatry. 145:1988;1094-1098.
41. Miller L., Griffith J. A comparison of bupropion, dextroamphetamine, and placebo in mixed-substance abusers. Psychopharmacology. 80:1983;199-205.
42. Oliveto A.H., Rosen M.I., Woods S.W., Kosten T.R. Discriminative stimulus, self-reported and cardiovascular effects of orally-administered cocaine in humans. J. Pharmacol. Exper. Ther. 272:1995;231-241.
43. Parsons L.H., Smith A.D., Justice J.B. Jr. Basal extracellular dopamine is decreased in the rat nucleus accumbens during abstinence from chronic cocaine. Synapse. 9:(1):1991;60-65.
44. Parsons L.H., Koob G.F., Weiss F. Serotonin dysfunction in the nucleus accumbens of rats during withdrawal after unlimited access to intravenous cocaine. J. Pharmacol. Exper. Ther. 274:1995;1182-1191.
45. Peck A.W., Hamilton M. Psychopharmacology of bupropion in normal volunteers. J. Clin. Psychiatry. 44:1983;202-205.
46. Peck A.W., Bye C.E., Clubley M., Henson T., Riddington C. A comparison of bupropion hydrochloride with dexamphetamine and amitriptyline in healthy subjects. Br. J. Clin. Pharmacol. 7:1979;469-478.
47. Preskorn S.H. Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine. J. Clin. Psychiatry. 56:1995;12-21.
48. Preston K.L., Sullivan J.T., Berger P., Bigelow G.E. Effects of cocaine alone and in combination with mazindol in human cocaine abusers. J. Pharmacol. Exper. Ther. 267:1993;296-307.
49. Richelson E., Pfenning M. Blockade by antidepressants and related compounds of biogenic amine uptake into rat brain synaptosomes: Most antidepressants selectively block norepinephrine uptake. Eur. J. Pharmacol. 114:1984;277-286.
50. Roose S.P., Glassman A.H., Giardina E.G., Johnson L.L., Walsh B.T., Bigger J.T. Jr. Cardiovascular effects of imipramine and bupropion in depressed patients with congestive heart failure. J. Clin. Psychopharmacol. 7:1987;247-251.
51. Rossetti Z.L., Melis F., Carboni S., Gessa G.L. Dramatic depletion of mesolimbic extracellular dopamine after withdrawal from morphine, alcohol or cocaine: A common neurochemical substrate for drug dependence. Ann. N.Y. Acad. Sci. 654:1992;513-516.
52. Rush C.R., Kollins S.H., Pazzaglia P.J. Discriminative-stimulus and participant-rated effects of methylphenidate, bupropion, and triazolam in D-amphetamine trained humans. Exper. Clin. Psychopharmacol. 6:1998;32-44.
53. Satel S.L., Price L.H., Palumbo J.M., McDougle C.J., Krystal J.H., Gawin F., Charney D.S., Heninger G.R., Kleber H.D. Clinical phenomenology and neurobiology of cocaine abstinence: A prospective inpatient study. Am. J. Psychiatry. 148:(12):1991;1712-1716.
54. Satel S.L., Kosten T.R., Schuckit M.A., Fischman M.W. Should protracted withdrawal be included in DSM-IV? Am. J. Psychiatry. 150:1993;695-704.
55. Volkow N.D., Fowler J.S., Wolf A.P., Schlyer D., Shiue C.Y., Alpert R., Dewey S.L., Logan J., Bendriem B., Christman D. Effects of chronic cocaine abuse on postsynaptic dopamine receptors. Am. J. Psychiatry. 147:(6):1990;719-724.
56. Walsh S.L., Preston K.L., Sullivan J.T., Fromme R., Bigelow G.E. Fluoxetine alters the effects of intravenous cocaine in humans. J. Clin. Psychopharmacol. 14:1994;396-407.
57. Walsh S.L., Sullivan J.T., Preston K.L., Garner J.E., Bigelow G.E. Effects of naltrexone on response to intravenous cocaine, hydromorphone and their combination in humans. J. Pharmacol. Exp. Ther. 279:1996;524-538.
58. Ward A.S., Haney M., Fischman M.W., Foltin R.W. Binge cocaine self-administration in humans: intravenous cocaine. Psychopharmacology. 132:1997a;375-381.
59. Ward A.S., Haney M., Fischman M.W., Foltin R.W. Binge cocaine self-administration by humans: smoked cocaine. Behav. Pharmacol. 8:1997b;736-744.
60. Ward A.S., Collins E.D., Haney M., Foltin R.W., Fischman M.W. Ketoconazole attenuates the cortical response but not the subjective effects of smoked cocaine in humans. Behav. Pharmacol. 9:1998;577-586.
61. Weddington W.W., Brown B.S., Haertzen C.A., Cone E.J., Dax E.M., Herning R.I., Michaelson B.S. Changes in mood, craving, and sleep during short-term abstinence reported by male cocaine addicts: A controlled, residential study. Arch. Gen. Psychiatry. 47:1990;861-868.
62. Weiss F., Markou A., Lorang M.T., Koob G.F. Basal extracellular dopamine levels in the nucleus accumbens are decreased during cocaine withdrawal after unlimited-access self-administration. Brain Res. 593:1992;314-318.
63. Weiss, F., Parsons, L.H., Lorang, M.T., Hyytia, P., Schulteis, G., Koob, G.F., 1994. Ethanol self-administration in dependent rats: Effects on dopamine and serotonin release in the nucleus accumbens. Annual Meeting of the Research Society on Alcoholism (RSA), Maui, Hawaii.
64. Wenger T.L., Stern W.C. The cardiovascular profile of bupropion. J. Clin. Psychiatry. 44:1983;176-182.
65. Wenger T.L., Cohn J.B., Bustrack J. Comparison of the effects of bupropion and amitriptyline on cardiac conduction in depressed patients. J. Clin. Psychiatry. 44:1983;174-175.
66. Willner P., Lappas S., Cheeta S., Muscat R. Reversal of stress-induced anhedonia by the dopamine receptor agonist, pramipexole. Psychopharmacology. 115:(4):1994;454-462.
67. Woods J.H., Katz J.L., Medzihradsky F., Smith C.B., Winger C.D. Evaluation of new compounds with opioid activity: 1982 annual report. NIDA Res. Monogr. 43:1983;457-511.